Dr David Straton. SSRIs Brands Citalopram Escitalopram Fluoxetine Fluvoxamine Paroxetine Sertraline...
Preview:
Citation preview
- Slide 1
- Dr David Straton
- Slide 2
- SSRIs Brands Citalopram Escitalopram Fluoxetine Fluvoxamine
Paroxetine Sertraline Cipramil, Celapram, Talam, Talohexal Lexapro,
Esipram Prozac, Auscap, Fluohexal, Lovan, Zactin Luvox, Faverin,
Movox Aropax, Oxetine, Paxtine Zoloft, Concorz, Eleva, Setrona,
Xydep
- Slide 3
- SNRIs Brands Desvenlafaxine Duloxetine Venlafaxine Pristiq
Cymbalta Efexor Others Bupropion (NDRI) Buspirone (Piperazine)
Mianserin (Tetracyclic) Mirtazapine (NaSSA) Moclobemide (RIMA)
Reboxetine (NRI) Tranylcypromine (MAOI) Zyban Buspar Tolvon, Lumin
Avanza, Axit 30, Mirtazon, Remeron Aurorix, Arima, Clobemix,
Maosig, Mohexal Edronax Parnate
- Slide 4
- Normal Synapse
- Slide 5
- Serotonin
- Slide 6
- Synapse in depression
- Slide 7
- SSRI increases serotonin 5HT1a
- Slide 8
- Some receptors may upregulate
- Slide 9
- SSRI effects 5HT1a Anxiety down, mood up 5HT2a Insomnia, sex
problems 5HT2c Agitation 5HT3 Nausea
- Slide 10
- Major studies and meta-analyses 2008-9 STAR*D (Sequenced
Treatment Alternatives to Relieve Depression). 26th Feb 2008, PLoS
Medicine published the Hull meta-analysis of anti- depressant
trials from the FDA. 18th Nov 2008, the American College of
Physicians published two background papers on anti-depressants.
28th Jan 2009, the Lancet published online a major meta-analysis of
antidepressants. 3rd Feb 2009, the Canadian Medical Association
Journal published a review of studies about whether SSRIs increase
the risk of suicide. June 2009, the Journal of Clinical
Psychopharmacology published a meta-analysis of anti-depressant
related sexual dysfunction. In August 2009, the BMJ published a
meta-analysis on suicidality.
- Slide 11
- STAR*D (Sequenced Treatment Alternatives to Relieve
Depression)
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- The Hull meta-analysis Attempt to avoid publication bias. FOI
on FDA, all clinical trials, both published and unpublished. Trials
with no benefit + no data left out. (Citalopram and sertraline).
Most trials only 6 weeks duration. Conclusion, drug only beat
placebo in most severe depressions.
- Slide 17
- Hull
- Slide 18
- The American College of Physicians Reviews Overall, no
substantial differences in efficacy Fluvoxamine lost every
comparison test for efficacy Venlafaxine prone to nausea Sertraline
prone to diarrhoea Mirtazapine prone to weight gain Venlafaxine and
paroxetine prone to discontinuation syndrome
- Slide 19
- Fluvoxamine compared to other anti-depressants ACP
- Slide 20
- Fluvoxamine compared to other anti-depressants
- Slide 21
- I.e Fluvoxamine lost every drug-to-drug contest ACP Fluvoxamine
compared to other anti-depressants
- Slide 22
- Lancet meta-analysis
- Slide 23
- Odds of being most effective 1) Mirtazapine24.4% 2)
Escitalopram23.7% 3) Venlafaxine22.3% 4) Sertraline20.3% 5)
Citalopram3.4% 6) Milnacipran2.7% 7) Bupropion2.0% 8)
Duloxetine0.9% 9) Fluvoxamine0.7% 10) Paroxetine0.1% 11)
Fluoxetine0.0% 12) Reboxetine0.0% Lancet
- Slide 24
- Odds of being most acceptable 1) Escitalopram27.6% 2)
Sertraline21.3% 3) Bupropion19.3% 4) Citalopram18.7% 5)
Milnacipran7.1% 6) Mirtazapine4.4% 7) Fluoxetine3.4% 8)
Venlafaxine0.9% 9) Duloxetine0.7% 10) Fluvoxamine0.4% 11)
Paroxetine0.2% 12) Reboxetine0.1% Lancet
- Slide 25
- Slide 26
- Suicide Risk (CMAJ) CMAJ
- Slide 27
- Slide 28
- Copyright 2009 BMJ Publishing Group Ltd. Odds of suicidality
(ideation or worse) for active drug relative to placebo by age in
adults Stone, M. et al. BMJ 2009
- Slide 29
- Suicide risk (BMJ) Suicidality risk vs placebo (ideation or
worse) in adults Drugn%Placebon%Odds ratio
Escitalopram1031300.32%526040.19%2.44
Citalopram2426610.90%713710.51%2.11
Fluvoxamine2221871.01%1318280.71%1.25
Mirtazapine810160.79%66440.93%0.97
Paroxetine5099190.50%2969720.42%0.93
Duloxetine2523271.07%1814601.23%0.88
Venlafaxine2955930.52%3039040.77%0.71
Fluoxetine8171801.13%6748141.39%0.71
Sertraline1863630.28%2850810.55%0.51 All
drugs314500430.63%197271640.73%0.83 BMJ
- Slide 30
- Sexual Side-effects TotalDesireArousalOrgasm
SevereSertraline27Citalopram55Citalopram82Clomipramine42
Venlafaxine25Paroxetine47Venlafaxine54Paroxetine18
Citalopram20Fluoxetine46Paroxetine44Venlafaxine16
Paroxetine17Sertraline43Sertraline39Sertraline15
Fluoxetine16Venlafaxine23Fluoxetine31Citalopram14
MildDuloxetine4Fluvoxamine6Duloxetine11Fluoxetine12
Escitalopram3Mirtazapine6Fluvoxamine7Mirtazapine4
Fluvoxamine3Duloxetine5Mirtazapine4Escitalopram4
Mirtazapine2Moclobemide4 2Fluvoxamine3
NilPlacebo1Escitalopram1Placebo1 1
Moclobemide0.2Placebo1Escitalopram0.7Moclobemide0.4 Serretti
- Slide 31
- S-(+)-citalopram (Escitalopram)R-(-)-citalopram 50/50 mixture
of both = Citalopram
- Slide 32
- Treatment algorithm: plan A Escitalopram. 2.5mg rising to 20
mg. Similar to Level 1 in STAR*D 2 nd for efficacy in Lancet
meta-analysis 1 st for acceptability in Lancet meta-analysis Mild
sex side-effects Trial should last at least 2 months. Possible
disadvantage if suicide risk high (BMJ)
- Slide 33
- Treatment algorithm: plan B (in no particular order) Add
thyroxine, esp if T4
- Slide 34
- Treatment algorithm: plan C California rocket-fuel Combination
of: Venlafaxine 75 300 mg Mirtazapine 30 60 mg
- Slide 35
- Treatments to abandon Fluvoxamine Reboxetine Augmentation with
lithium for unipolar depression
- Slide 36
- Treatments to downplay Paroxetine Antidepressants in
adolescents, especially venlafaxine and paroxetine
- Slide 37
- Treatments in danger of being abandoned prematurely
Tranylcypromine. 'Approximately 30% of participants in the
tranylcypromine group had less than 2 weeks of treatment, and
nearly half had less than 6 weeks of treatment (STAR*D)
- Slide 38
- Papers mentioned available here:
psyberspace.com.au/depression